Redeye provides an update on Adverty following its Q3 2022 report.
Redeye updates its estimates following Sleep Cycle's preliminary Q4 2022 numbers.
Redeye comments on Azelio’s updated guidance released last night.
We expect Netcompany to deliver according to its 2022 guidance, resulting in a solid Q4 that include...
Recyctec fortsätter växa med ett fortsatt fokus på försäljning, både på den inhemska och utländska m...
Eurocon Consulting är ett konsultbolag som erbjuder expertis och rådgivning inom en rad olika område...
Redeye comments on Sleep Cycle's preliminary Q4 2022 numbers.
Redeye är positiva till morgonens besked att BioArctics partner Eisai ansökt om marknadsgodkännande ...
Partneravtalet omfattar hela CAG:s tjänsteutbud BAE Systems Hägglunds är sedan tidigare kund till CA...
Redeye is favourable towards the new preclinical results with CAN10 but believes that the share pric...
Absolicon Solar Collector AB är ett svenskt bolag som utvecklar, tillverkar och säljer robotiserade ...
Magnitude of soft year-end misunderstood In mid-December, Fiskars communicated an expected FY'22 adj...
Relais’ CFO Pekka Raatikainen is stepping down by the end of June to pursue career outside the compa...
Redeye states that the announced extension agreement in Operating Systems indicates a slower decline...
IRLAB Therapeutics has announced that it has selected a drug candidate from its P003 discovery progr...
Förvärvet av UBConnect exemplifierar strategin… Transtema planerar att växa i tre dimensioner – i nä...
Redeye comments on AVTECH's preliminary numbers for Q4'22 which was largely in line with our estimat...
OrderYOYO announced on Thursday, January 12th, the company’s performance during Q4-22.
Redeye states that Neonode’s patent 879 is judged not to be unpatentable – implying a crucial win fo...
Redeye is encouraged by Adverty's momentum in increasing its reach on the supply side and the increa...
